StreetInsider.com News Articles

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26928751.html

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26928751.html

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926674.html

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926674.html

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26925077.html

Form SCHEDULE 13G/A MoonLake Immunotherapeut Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26925077.html

Moonlake Immunotherapeutics (MLTX) PT Raised to $50 at H.C. Wainwright

Thu, 13 Aug 2026 06:55:21 -0400

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $50.00 (from $40.00) while maintaining a Buy rating.

Form S-8 MoonLake Immunotherapeut

Mon, 10 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260810/26898727.html

Form S-8 MoonLake Immunotherapeut

Mon, 10 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260810/26898727.html

Form S-3ASR MoonLake Immunotherapeut

Mon, 10 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260810/26898661.html

Form S-3ASR MoonLake Immunotherapeut

Mon, 10 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260810/26898661.html

MoonLake Immunotherapeutics (MLTX) Tops Q2 EPS by 9c

Mon, 10 Aug 2026 08:04:28 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q2 EPS of ($0.84), $0.09 better than the analyst estimate of ($0.93).

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

Form 10-Q MoonLake Immunotherapeut For: Jun 30

Mon, 10 Aug 2026 07:47:00 -0400

si-local-file:///var/storage/secattach/20260810/26894503.html

Form 10-Q MoonLake Immunotherapeut For: Jun 30

Mon, 10 Aug 2026 07:47:00 -0400

si-local-file:///var/storage/secattach/20260810/26894503.html

Form 8-K MoonLake Immunotherapeut For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894264.html

Form 8-K MoonLake Immunotherapeut For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894264.html

MoonLake's psoriatic arthritis trial meets all endpoints at week 16

Mon, 10 Aug 2026 07:00:19 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported positive topline results from its Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis, according to a company press release.

The trial met its primary endpoint, with 42.1% of patients treated with sonelokimab 60 mg with induction achieving an ACR50 response at Week 16. Key secondary endpoints were also met: 66.5% of patients achieved ACR20, 41.2% achieved Minimal Disease Activity, and 61% of patients with skin involvement achieved PASI90. Patient-reported outcomes showed a mean change from baseline in HAQ-DI of -0.427 and an SF-36 Physical Component Summary score improvement of 6.54.

A blinded

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second

Mon, 10 Aug 2026 07:00:00 -0400

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab
The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis
Meaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS
Blinded safety analysis suggests a profile consistent with previous studies

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second

Mon, 10 Aug 2026 07:00:00 -0400

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab
The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis
Meaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS
Blinded safety analysis suggests a profile consistent with previous studies

Form 4 MoonLake Immunotherapeut For: Jul 27 Filed by: Reich Kristian

Wed, 29 Jul 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260729/26835077.html

Form 4 MoonLake Immunotherapeut For: Jul 27 Filed by: Reich Kristian

Wed, 29 Jul 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260729/26835077.html

Form 4 MoonLake Immunotherapeut For: Jul 20 Filed by: Reich Kristian

Wed, 29 Jul 2026 15:46:00 -0400
si-local-file:///var/storage/secattach/20260729/26834596.html

Form 4 MoonLake Immunotherapeut For: Jul 20 Filed by: Reich Kristian

Wed, 29 Jul 2026 15:46:00 -0400
si-local-file:///var/storage/secattach/20260729/26834596.html

Form 4 MoonLake Immunotherapeut For: Jul 21 Filed by: Reich Kristian

Thu, 23 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260723/26808005.html

Form 4 MoonLake Immunotherapeut For: Jul 21 Filed by: Reich Kristian

Thu, 23 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260723/26808005.html